These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35417485)

  • 1. Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial.
    Velloza J; Poovan N; Ndlovu N; Khoza N; Morton JF; Omony J; Mkwanazi E; Grabow C; Donnell D; Munthali R; Baeten JM; Hosek S; Celum C; Delany-Moretlwe S
    PLoS One; 2022; 17(4):e0266665. PubMed ID: 35417485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
    Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
    PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
    Celum CL; Gill K; Morton JF; Stein G; Myers L; Thomas KK; McConnell M; van der Straten A; Baeten JM; Duyver M; Mendel E; Naidoo K; Dallimore J; Wiesner L; Bekker LG
    J Int AIDS Soc; 2020 Nov; 23(11):e25636. PubMed ID: 33247553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa-study protocol.
    Medina-Marino A; Bezuidenhout D; Hosek S; Barnabas RV; Atujuna M; Bezuidenhout C; Ngwepe P; Peters RPH; Little F; Celum CL; Daniels J; Bekker LG
    Trials; 2021 Jul; 22(1):489. PubMed ID: 34311754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study.
    Beauchamp G; Hosek S; Donnell DJ; Chan KCG; Flaherty BP; Anderson PL; Dye BJ; Mgodi N; Bekker LG; Delany-Moretlwe S; Celum C;
    PLoS One; 2023; 18(2):e0281728. PubMed ID: 36827440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 study.
    Beauchamp G; Donnell D; Hosek S; Anderson PL; Chan KCG; Dye BJ; Mgodi N; Bekker LG; Delany-Moretlwe S; Celum C
    BMC Womens Health; 2023 May; 23(1):276. PubMed ID: 37208687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
    Stranix-Chibanda L; Anderson PL; Kacanek D; Hosek S; Huang S; Nematadzira TG; Taulo F; Korutaro V; Nakabiito C; Masenya M; Lypen K; Brown E; Ibrahim ME; Yager J; Wiesner L; Johnston B; Amico KR; Rooney JF; Chakhtoura N; Spiegel HML; Chi BH;
    Clin Infect Dis; 2021 Oct; 73(7):e1893-e1900. PubMed ID: 33341883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
    Celum CL; Bukusi EA; Bekker LG; Delany-Moretlwe S; Kidoguchi L; Omollo V; Rousseau E; Travill D; Morton JF; Mogaka F; O'Malley G; Barnabee G; van der Straten A; Donnell D; Parikh UM; Kudrick L; Anderson PL; Haberer JE; Wu L; Heffron R; Johnson R; Morrison S; Baeten JM;
    J Int AIDS Soc; 2022 Jul; 25(7):e25962. PubMed ID: 35822945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
    Tapsoba JD; Cover J; Obong'o C; Brady M; Cressey TR; Mori K; Okomo G; Kariithi E; Obanda R; Oluoch-Madiang D; Chen YQ; Drain P; Duerr A
    PLoS Med; 2022 Sep; 19(9):e1004097. PubMed ID: 36095005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
    Matthews LT; Atukunda EC; Owembabazi M; Kalyebera KP; Psaros C; Chitneni P; Hendrix CW; Marzinke MA; Anderson PL; Isehunwa OO; Hurwitz KE; Bennett K; Muyindike W; Bangsberg DR; Haberer JE; Marrazzo JM; Bwana MB
    PLoS Med; 2023 Feb; 20(2):e1004088. PubMed ID: 36795763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
    Velloza J; Donnell D; Hosek S; Anderson PL; Chirenje ZM; Mgodi N; Bekker LG; Marzinke MA; Delany-Moretlwe S; Celum C
    Lancet HIV; 2022 Oct; 9(10):e680-e689. PubMed ID: 36087612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
    van den Elshout MA; Hoornenborg E; Coyer L; Anderson PL; Davidovich U; de Vries HJ; Prins M; Schim van der Loeff MF;
    Sex Transm Infect; 2023 Aug; 99(5):303-310. PubMed ID: 37258273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing HIV pre-exposure prophylaxis outcomes among Kenyan adolescent girls and young women with a novel pharmacy-based PrEP delivery platform: protocol for a cluster-randomized controlled trial.
    Lagat HK; Pintye J; Harrington E; Houck S; Kwena Z; Lenn M; Mogaka F; Momanyi V; Mugambi M; Nyerere B; Odoyo J; Omollo V; Ortblad KF; Rota G; Sharma M; Bukusi EA
    Trials; 2024 Jun; 25(1):394. PubMed ID: 38890744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
    Songtaweesin WN; Kawichai S; Phanuphak N; Cressey TR; Wongharn P; Saisaengjan C; Chinbunchorn T; Janyam S; Linjongrat D; Puthanakit T;
    J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre-exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial.
    Velloza J; Hosek S; Donnell D; Anderson PL; Chirenje M; Mgodi N; Bekker LG; Delany-Moretlwe S; Celum C;
    J Int AIDS Soc; 2021 Jun; 24 Suppl 2(Suppl 2):e25731. PubMed ID: 34164929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
    Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
    J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the use of oral pre-exposure prophylaxis among pregnant and postpartum adolescent girls and young women in Cape Town, South Africa.
    Khadka N; Gorbach PM; Nyemba DC; Mvududu R; Mashele N; Javanbakht M; Nianogo RA; Aldrovandi GM; Bekker LG; Coates TJ; Myer L; Joseph Davey DL
    Front Reprod Health; 2023; 5():1224474. PubMed ID: 37795521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stepped care to optimize pre-exposure prophylaxis (PrEP) effectiveness in pregnant and postpartum women (SCOPE-PP) in South Africa: a randomized control trial.
    Joseph Davey DL; Dovel K; Cleary S; Khadka N; Mashele N; Silliman M; Mvududu R; Nyemba DC; Coates TJ; Myer L
    BMC Public Health; 2022 Jul; 22(1):1306. PubMed ID: 35799121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High study participation but diverging adherence levels: qualitatively unpacking PrEP use among adolescent girls and young women over two years in Eastern Cape, South Africa.
    Krogstad Mudzingwa E; de Vos L; Atujuna M; Fynn L; Mugore M; Mabandla S; Hosek S; Celum C; Bekker LG; Daniels J; Medina-Marino A
    J Behav Med; 2024 Apr; 47(2):320-333. PubMed ID: 38081955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.